Prevention of asprin-induced small-intestinal injury by Poraprezinc

Prevention of asprin-induced small-intestinal injury by Poraprezinc - Prevention of asprin-induced small-intestinal injury by Poraprezinc

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003687

Enrollment

Registered

2010-06-01

Start date

2010-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

small-intestinal injury

Interventions

taking Poraprezinc for 4 weeks follow-up without any medication

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. History of taking Asprin 2. With no antibiotic substance 3. Negative for disease germ from feces examination 4. Over 20 years old 5. Agreement of informed concent

Exclusion criteria

Exclusion criteria: 1. Patients with inflammatory bowel disease 2. Patients with digestion and absorption disorder 3. Patients who is taking Poraprezinc 4. Patients who is taking other medicines for gastritis, such as Misoprostol, Rebamipide, etc. 5. Patients who is taking Penicillamine and Levothyroxine sodium 6. Patients with stenosis of gastrointestinal tract and severe adhesion 7. Pregnant and nursing women 8. Patients with severe ulcerative lesion with capsule endoscopy

Design outcomes

Primary

Measure	Time frame
1. Incidence of asprin-induced small-intestinal injury (redness, erosion, ulcer) 2. Evaluation of endoscopic findings with capsule endoscopy after taking Poraprezinc or not.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026